Corus制药控股 CRBP 深 沪
已收盘 10-31 16:00:00 美东时间
12.15
-4.290
-26.09%
华盛通- 最 高12.88
- 今 开12.00
- 成交量 290.07万股
- 最 低 11.59
- 昨 收 16.44
- 总市值 1.49亿
- 52周最高 20.56
- 市盈率 静 --
- 换手率 23.67%
- 52周最低 4.64
- 委 比 -73.91%
- 总股本 1225.52万
- 历史最高 323.40
- 量 比 11.09
- 振 幅 7.85%
- 历史最低 3.00
- 每 手 1
- 风险率 3.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share
Corbus Pharmaceuticals (CRBP) priced an underwritten public offering of ~4.74M shares at $13.00 per share and pre-funded warrants to purchase ~1.03M shares, for a total public offering size of ~$75M...
10-31 18:10
Corbus Pharmaceuticals Announces Preliminary Q3 Financials
The latest update is out from Corbus Pharmaceuticals ( ($CRBP) ). Corbus Pharma...
10-31 05:21
Corbus Pharmaceuticals Holdings shares are trading lower after the company announced a proposed public offering.
Corbus Pharmaceuticals Holdings shares are trading lower after the company anno...
10-31 04:49
Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharmaceuticals Holdings, Inc. plans to offer and sell shares of its common stock or pre-funded warrants in an underwritten public offering, subject to market conditions. Proceeds will fund clinical development of its pipeline and general corporate purposes. Jefferies LLC and Piper Sandler & Co. will act as joint book-running managers. The SEC has declared the registration statement effective, and a preliminary prospectus supplement will b...
10-30 20:31
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
Corbus Pharmaceuticals announced interim data from its Phase 1/2 study of CRB-701, an antibody-drug conjugate targeting Nectin-4, at the ESMO25 Congress. The study showed objective response rates (ORR) of 47.6%, 37.5%, and 55.6% in head and neck squamous cell carcinoma (HNSCC), cervical cancer, and metastatic urothelial cancer (mUC), respectively, at a 3.6 mg/kg dose. CRB-701 demonstrated a favorable safety profile with no grade 4 or 5 treatment-...
10-18 07:00
Corbus Pharmaceuticals Releases Abstract For Its Phase 1/2 Oncology Study Ahead Of Presentation At ESMO Congress 2025. Abstract Includes Safety Data From 70 Participants
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 abstract for its Phase 1/2
10-14 20:07
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Corbus Pharmaceuticals announced the release of an abstract for their Phase 1/2 clinical study of CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4, to be presented at the European Society for Medical Oncology (ESMO) Congress 2025. The study involves 167 enrolled participants, with 122 evaluable for efficacy across various tumor types, including head and neck squamous cell carcinoma (HNSCC), cervical, and metastatic urothelial...
10-14 12:00
稳定币崛起 比特币的“货币支付梦”还能实现吗？
随着《GENIUS法案》巩固了由美国国债支持的稳定币地位，比特币凭借其去中心化特性成为推动数字美元革命的优越选择，应对多极化世界中美元需求下降的趋势。文章讨论了世界秩序从单极向多极的转变，美元面临的压力，以及比特币作为区块链网络的优势。稳定币在全球范围内的普及，尤其是在发展中国家，显示了美元需求的潜在增长。比特币的去中心化、隐私性和安全性使其成为未来全球经济的重要基础设施。 总结：《GENIUS法案》巩固了美元稳定币地位，比特币因其去中心化特性成为全球区块链的首选，应对多极化世界中美元需求下降的趋势。文章指出比特币独特的安全性与隐私性使其适合推动数字美元革命，确保美元在全球经济中的地位。
10-06 03:24
